class of disease | Q112193867 |
serous carcinoma | Q7455058 |
ovarian carcinoma | Q18556145 |
ovarian serous tumor | Q19000698 |
P699 | Disease Ontology ID | DOID:0050933 |
P2888 | exact match | http://identifiers.org/doid/DOID:0050933 |
http://purl.obolibrary.org/obo/DOID_0050933 | ||
P11956 | Experimental Factor Ontology ID | 0002917 |
P5008 | on focus list of Wikimedia project | WikiProject Medicine | Q4099686 |
Q92336127 | A Comprehensive Review of Ovarian Serous Carcinoma |
Q91470904 | A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma |
Q35980522 | A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006 |
Q82293644 | A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases |
Q88072881 | APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival |
Q85655227 | AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma |
Q40115732 | Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. |
Q85327489 | Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance |
Q40523803 | B7-H4 expression in ovarian serous carcinoma: a study of 306 cases |
Q92845245 | Bleeding and bowel obstruction in giant ovarian serous carcinoma - a video vignette |
Q44261967 | Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases |
Q26998068 | Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma |
Q98499784 | Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma |
Q79918669 | Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma |
Q64115689 | Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers |
Q35575176 | Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. |
Q92248873 | Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma |
Q84782227 | Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology |
Q55452489 | Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer. |
Q33751321 | Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight |
Q67947147 | Comparison of cellular phenotypes in tumor cyst and ascitic fluid from ovarian serous carcinoma |
Q72632226 | Concurrent ovarian serous carcinoma and osteogenesis imperfecta |
Q92131983 | Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma |
Q46314878 | Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion |
Q53286591 | Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. |
Q92524991 | Differential expression of immune related genes in high-grade ovarian serous carcinoma |
Q33233449 | Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma |
Q38971615 | ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy |
Q34978084 | Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status |
Q39208636 | Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients |
Q74099950 | Evaluation of a region on chromosome 1p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma |
Q80262379 | Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma |
Q41219933 | Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival |
Q44544392 | Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium |
Q81475966 | Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival |
Q44053802 | Expression of cyclooxygenase-2 in ovarian serous carcinoma: correlation with angiogenesis, nm23 expression and survival. |
Q37388641 | Expression of p-Akt in ovarian serous carcinoma and its association with proliferation and apoptosis |
Q37229341 | Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival |
Q39203802 | FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome |
Q37050667 | Gene Set-Based Functionome Analysis of Pathogenesis in Epithelial Ovarian Serous Carcinoma and the Molecular Features in Different FIGO Stages |
Q44618222 | Glycodelin in ovarian serous carcinoma: association with differentiation and survival. |
Q79934949 | Grading ovarian serous carcinoma using a two-tier system |
Q83811112 | HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases |
Q83188780 | HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma |
Q45953122 | HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. |
Q51753726 | High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. |
Q47150076 | High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism |
Q89421055 | Immunostaining Study on the Expression of NF-κB, ER, and PR in Ovarian Serous Carcinoma |
Q92332337 | Influence of marital status on overall survival in patients with ovarian serous carcinoma: finding from the surveillance epidemiology and end results (SEER) database |
Q53082153 | Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis. |
Q57791800 | Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis |
Q80456258 | Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma |
Q91812790 | Low Grade Ovarian Serous Carcinoma - A Clinical-Morphologic Study |
Q74310041 | Malignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases |
Q91648665 | Mediastinal metastasis from ovarian serous carcinoma 29 years after initial treatment |
Q92321835 | Metastatic Carcinoma of Endometrium from Primary Ovarian Serous Carcinoma Mimicking a Primary Uterine Tumour |
Q62112710 | Metastatic Ovarian Serous Carcinoma Presenting as Inflammatory Breast Cancer: A Case Report |
Q48164105 | Metastatic Ovarian Serous Carcinoma of the Breast. |
Q36553567 | Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases |
Q36037099 | Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma |
Q73144573 | Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma |
Q33327971 | NM23 as a prognostic biomarker in ovarian serous carcinoma |
Q103738182 | Osseous Metaplasia in Low-grade Ovarian Serous Carcinoma With a BRAF Mutation: A Case Report |
Q46008296 | Ovarian serous carcinoma associated with a distinct "corded and hyalinized" pattern. |
Q92867921 | Ovarian serous carcinoma in synthetic mesh: A rare case report and review of the literature |
Q57764870 | Ovarian serous carcinoma presenting with mediastinal lymphadenopathy 20 months before the intraabdominal mass: Role of immunohistochemistry |
Q26822545 | Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis |
Q85055443 | Ovarian serous carcinoma: relationship of p53 and bcl-2 with tumor angiogenesis and VEGF expression |
Q40389999 | PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors |
Q30434644 | PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma |
Q58088279 | Peritoneal Carcinomatosis From Yolk Sac Tumor in a Postmenopausal Woman Following Chemotherapy for High-grade Ovarian Serous Carcinoma |
Q80550802 | Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma |
Q38306666 | Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions |
Q86746941 | Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma |
Q30461903 | Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma |
Q46988991 | Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis |
Q64083343 | Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma |
Q89868575 | Surprise Lymph Node Histology in a Patient with Ovarian Serous Carcinoma |
Q71544451 | Syndrome of inappropriate antidiuresis in ovarian serous carcinoma with neuroendocrine differentiation |
Q36624703 | The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma |
Q41747755 | The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions |
Q79080812 | The effect of cyclooxygenase‐2 expression on tumor vascularity in advanced stage ovarian serous carcinoma |
Q100497506 | The immune complex p53 protein/anti-p53 autoantibodies in the pathogenesis of ovarian serous carcinoma |
Q81872426 | The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma |
Q95499783 | Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site |
Q81377645 | Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma |
Q50663650 | VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. |
Q81223439 | Virchow's node as a first manifestation of ovarian serous carcinoma: case report |
Q83415067 | [Clinical significance of two-tier grading system of ovarian serous carcinoma] |
Q82986986 | [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma] |
Q83249807 | [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma] |
Q73153525 | beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma |
Q39145559 | miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1. |
Q18556985 | ovary serous adenocarcinoma | subclass of | P279 |
Q28444998 | CD274 Expression | positive prognostic predictor for | P3358 |
Category:Ovarian serous carcinoma | wikimedia |
Search more.